Are current avian influenza vaccines a solution for smallholder poultry farmers? by Peters, Andrew & Guyonnet, Vincent
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Are current avian influenza vaccines a solution for smallholder
poultry farmers?
Citation for published version:
Peters, A & Guyonnet, V 2020, 'Are current avian influenza vaccines a solution for smallholder poultry
farmers?', Gates Open Research.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Gates Open Research
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Oct. 2020
OPEN LETTER
Are current avian influenza vaccines a solution for 
smallholder poultry farmers?
Vincent Guyonnet1, Andy R. Peters 2
1FFI Consulting Ltd., Brockville, Ontario, Canada 
2Supporting Evidence Based Interventions (SEBI), University of Edinburgh, Edinburgh, UK 
First published: N/A, N/A: N/A N/A
Latest published: N/A, N/A: N/A N/A
v1
Abstract 
Vaccination against highly pathogenic avian influenza (HPAI) viruses, 
along with other measures, was successful in eradicating AI in very 
few countries where the competence of national veterinary services or 
the geography and bird density have contributed favorably to the 
outcome.  The main constraints to an effective AI vaccination are 
vaccine composition matching field strains, reliable cold chain and 
logistics to target all poultry smallholders, constraints related to the 
availability of sufficient financial and human resources.  When not 
conducted properly, vaccination can also contribute to the emergence 
of new field viral strains, through genetic drifts of HPAI viruses.   While 
new technologies have improved the possibility to produce high 
quality vaccines matching field strains, recurrent issues like post-
vaccination field surveillance and vaccination coverage continue to 
limit the relevance of AI vaccination in smallholder settings. A “game-
changer” vaccine targeting smallholders should be universal to 
protect against all field viral strains and reduce significantly, if not 
totally eliminate, the need for costly post-vaccination surveillance.  
The ease of administration of this vaccine (eye drop or one single 
injection) would further contribute to its relevance in the field.  These 
characteristics are considered essential for the product profile of an AI 
vaccine that can contribute in a meaningful way to the livelihoods of 
poultry smallholders.
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Introduction
Although more than 30 epizootics of high pathogenicity 
Avian Influenza (HPAI) have been reported in poultry (Gallus 
domesticus) and other birds since 1959, vaccination of Poultry 
has only been added as a control tool since 1995 (Swayne 
et al., 2014). In recent outbreaks, vaccination has been used 
only in about 19% of the countries experiencing HPAI 15 
countries out of 80 countries), showing that vaccination is 
not the most common and immediate response to an outbreak 
(Swayne et al., 2011). The nature of the AI virus, with the 
rapid emergence of new field viral strains, through genetic drifts 
of HPAI viruses, has affected the effectiveness of vaccines. 
Vaccination along with other measures has been successful in 
eradicating AI in very few countries where the competence of 
national veterinary services (e.g. France, the Netherlands) or the 
geography and bird density (Hong Kong) have favorably con-
tributed to the outcome. In the four countries (China, Egypt, 
Indonesia and Vietnam) where massive vaccination cam-
paigns have been initiated since 2004 (accounting for more than 
99% of the use of AI vaccines), HPAI virus is now endemic, 
outlining the difficulty to eradicate AI in countries with a high 
percentage of backyard poultry (Swayne et al., 2011). A number 
of factors are limiting the effectiveness of AI vaccination in 
smallholder settings and are discussed in the following sec-
tions along with the characteristics of the ideal vaccine to target 
the poultry smallholder segment.
AI – etiology and epidemiology
Influenza viruses belong to the Orthomyxoviridae family, caus-
ing respiratory disease of the upper respiratory tract in humans, 
avian species, and a variety of mammal species. Orthomyxo-
viruses are classified as Types A, B or C with Avian influenza 
caused by a highly mutable Type A influenza virus.
The replication of this single stranded RNA virus is highly vari-
able, resulting in a constantly evolving and highly mutable virus 
(Swayne et al., 2013). The lipid envelope of the virus makes it 
unstable and relatively susceptible to environmental destruction 
from ultraviolet light, chemicals, or desiccation. The hemag-
glutinin (HA or H) antigen is a protein providing the mechanism 
for the entry into the host cell while the neuraminidase (NA or 
N) protein allows the exit of newly replicated virions from the 
host cells. The HA protein is the major antigen stimulating the 
host immune response with protective antibodies against 
clinical signs and mortality. There are at least 16 H strains and 
9 N strains, which can result in 144 possible HN combinations. 
This forms the basis of the serological classification using the 
hemagglutinin inhibition and neuraminidase inhibition tests. The 
nomenclature of the virus is based on the HN subtype, influenza 
type, host species, sample location, strain number and year of 
isolation, e.g. H5N1 A/goose/Guangdong/1/1996.
The antigenic variation of the HA and NA surface glycopro-
teins occurs at a high frequency through minor “drift” changes 
and may be associated with the immune pressure exerted by 
the vaccination of birds. Major antigenic “shift” in the HA 
and NA coding proteins, the result of genetic re-assortment 
between gene segments of two different influenza virus strains 
(subtypes) in host cells, commonly occurs especially when 
domestic waterfowl and poultry are in close proximity as often 
seen in developing countries under smallholder settings. Ducks 
are often silent carriers of the AI virus, constituting an addi-
tional challenge for the control of AI (Swayne et al., 2013). 
AI viruses in poultry are classified as either low pathogenic 
(LPAI) or highly pathogenic (HPAI), based on the clinical signs 
and mortality, using the definition established by the World 
Organization for Animal Health (OIE, 2018). During the period 
January 2013 to February 2019, HPAI in domestic poul-
try was reported in 68 countries and territories with a total of 
7,270 outbreaks (OIE, 2019). In most of the countries in Asia 
and Africa, the poultry sector is dominated by smallholder 
farmers.
During the same period, a total of 12 subtypes of AI viruses 
were reported (OIE, 2019), with subtypes H5N1, H5N2 and 
H5N8 widespread and more frequently reported (Table 1).
LPAI outbreaks with viruses of H5 and H7 subtypes are also 
reportable to the OIE as there is a risk of the viruses becom-
ing highly pathogenic by mutation. During the period January 
2013–February 2019, the vast majority of these outbreaks 
were reported in Asia, Europe, the Americas and a few in 
Africa (mainly in South Africa).
H5N1 HPAI viruses have been sub-classified according to 
Clades, or groups of AI viruses that share a common ancestor 
(WHO, 2011). There are at least 10 Clade groups currently 
identified by the OIE and FAO network of expertise on animal 
influenza (OFFLU). Both antigenic shift and drift are important 
mechanisms for the evolution of the virus. The presence of 
co-circulating subtypes among dense populations of birds adds 
extra pressure for antigenic shift. Intrinsic subtype specific 
antigenic drift is associated with the frequency and distribu-
tion of infection in a poultry population as naive populations 
become exposed to new variants. Vaccination is also believed 
to exert a selection pressure on the virus by increasing the 
mutation rate by several orders of magnitude (Swayne et al., 
2014). In addition, the evolution of new clade types can 
change the morbidity and mortality. Prior to 2012, clade 2.2 
(Indonesia) and clade 1.1 (Cambodia) were predominant, with 
mortality in domestic ducks of less than 10%. Following the 
introduction of clade 3.2.1, the mortality reported in ducks 
is greater than 40% and up to 90% depending on the age of 
Table 1. Distribution of different HPAI subtypes in 
domestic birds, by region (January 2013 – February 
2019).
Region HPAI subtypes
Africa H5N1, H5N2, H5N8
Americas H5N1, H5N2, H5N8, H7N3, H7N8, H7N9
Asia H5N1, H5N2, H5N3, H5N6, H5N8, H7N9
Europe H5N1, H5N2, H5N5, H5N6, H5N8, H5N9, H7N7
Oceania H7N2
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the ducks. As a virus is transferred from wild birds to poultry, 
natural selection within the host favours greatly adapted strains, 
which often become more pathogenic for both LPAI and 
HPAI pathotypes (Swayne et al., 2013).
The type of poultry production is also critical to assess the 
risk of exposure. Birds kept for longer periods (laying hens, 
breeder birds and slow-growth meat birds) have a longer 
duration of potential exposure to AI virus than short-lived 
poultry (broiler-type meat birds). The concurrent presence of 
immunosuppressive agents and conditions for example, reduce 
the  infectious dose and has been associated with morbidity and 
mortality due to both LPAI and HPAI infections. Therefore, gen-
eral health screening for concurrent diseases in poultry, often 
difficult to achieve under smallholder settings, is important 
during immunization and for the overall control of avian influenza. 
AI outbreaks during the period January 2013–February 2019 
resulted in the loss of approximately 128 million birds, with 
more than half (57.6%) of the reported losses in Asia, followed 
by the Americas (22.1%) and Europe (13.4%) (OIE, 2019). 
Losses in Africa accounted for only 6.5% of the total losses 
(Table 2).
AI vaccines and vaccination
AI vaccine types and production
Poultry AI vaccines used in the field are based on five technolo-
gies: 1) wild-type or reverse genetics whole AI virus grown in 
embryonated chicken eggs, then chemically inactivated and 
adjuvanted; 2) HA antigen or virus-like particles produced in 
insect cells by a genetically engineered baculovirus; 3) HA 
DNA vaccine adjuvanted; 4) recombinant technologies utiliz-
ing live virus vectors to express AI virus HA and in some cases 
NA gene inserts (recombinant Herpes turkey virus (rHVT-
AIV), recombinant Newcastle disease virus (rNDV-AIV) and 
recombinant Fowl pox virus (rFPV-AIV)) and, 5) defective-
replicating alphavirus (defective Venezuelan Equine Encepha-
litis virus with H5 AI virus gene insert (D. E. Swayne, personal 
communication). 
The recombinant ND-vectored vaccines used for the control of 
AI are broadly divided into two categories (Suarez et al., 2017). 
One alternative uses reverse genetic technology to insert 
an AI gene sequence coding for a specific protein into the 
ND virus thus producing a recombinant ND virus express-
ing that protein. After viral multiplication in embryonated 
chicken eggs, the recombinant viruses recovered are inactivated 
and adjuvanted for the production of the AI vaccine. This 
technology was recently patented in the USA by Laboratorio 
Avimex (Lozano-Dubernard et al., 2015) and presents the 
advantage of being safe to use in BSL-2 production facilities, 
more readily available in developing countries.
The second alternative applies the reverse technology to produce 
live ND vector vaccine viruses, often using the more aggres-
sive LaSota vaccinal strain as the backbone, which express HA 
genes (H5, H6, H7 and H9 inserts). One of the primary benefits 
of this alternative is that the live virus replicates on mucosal 
surfaces, can be administered by mass application such as 
water or aerosol application, thus reducing the overall cost of 
vaccination and may be administered to other species of poul-
try, especially ducks. Conversely, one of the main concerns is 
related to the level of maternal ND antibodies in chicks which 
may interfere with the replication of the recombinant ND 
viruses and overall efficacy of the vaccine. In addition to being 
considered as genetically modified organisms, the potential 
of live ND vectored vaccines to spread to non-target spe-
cies and to unvaccinated flocks often raises concerns dur-
ing the regulatory review and vaccine licensing process 
(Suarez et al., 2017). 
There are several new experimental AI vaccine approaches not 
currently licensed for commercial use including wild type or 
attenuated LPAI; use of various vectors e.g. adenovirus, salmo-
nella, avian leukosis and vaccinia; eukaryotic systems e.g. plants; 
and DNA vaccines, with a main objective being a universal 
vaccine covering against all subtypes of HPAI. Of course, this 
would be an ideal scenario. However current opinion is that 
there is little expectation that such vaccine will be developed 
to licensure in the foreseeable future (e.g. Swayne et al., 2019).
Multivalent vaccines commercially available
Review of the vaccine database from The Center for Food 
Security and Public Health, Iowa State University showed that 
of 43 manufacturers listing vaccines for the control of Avian 
Influenza, 31 (72%) are currently manufacturing vaccines 
combining AI with other antigens (CFSPH, 2018). These man-
ufacturers are based in 11 different countries on five conti-
nents but the majority of them (71%) are located in Asia (22 of 
the 31) where AI vaccination has been practiced since 1995. 
Manufacturers located in Europe and North America are 
producing vaccines mostly for export and for the setting-up 
of emergency stocks. There is currently just one manufacturer 
of AI vaccines on the African continent, although it is believed 
that others are at a planning stage.
The combination vaccines produced are either AI + ND only 
(26 manufacturers, 84%), AI +ND + other antigens (15 manu-
facturers, 48%) and AI + another antigen but not ND (3 manu-
facturers, 10%), these numbers accounting for the fact that 
some manufacturers are producing more than one type of AI 
combination vaccine. 
Table 2. Distribution of mortality in 
domestic birds, by region (January 
2013 – February 2019).
Region Losses Percentage 
of total
Africa 8,339,384 6.5%
Americas 28,224,324 22.1%
Asia 73,673,631 57.6%
Europe 17,187,364 13.4%
Oceania 490,000 0.4%
Total 127,914,703 100 %
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Use of AI combination vaccines by the poultry sector
Based on the list of antigens combined with AI presented pre-
viously, it is evident that these vaccines are mostly used in 
the egg laying and breeder poultry sectors and not by poul-
try smallholders. As might be expected from this wide range 
of vaccines and the disease challenges experienced in the field, 
there are a multitude of vaccination schedules used by poultry 
producers. 
As an example, a recent study in Indonesia by Tarigan et al. 
(2018) showed that there were broadly three types of sched-
ule for the administration of AI vaccines to commercial laying 
birds:
-   two or three vaccinations before 19 weeks of age (start of laying 
period)
-   two vaccinations before 19 weeks of age and one vaccination 
after 19 weeks
-   three or four vaccinations before 19 weeks and 2 or 3 vaccina-
tions after 19 weeks
Irrespective of the vaccination schedule or the specific vac-
cines used, Tarigan et al. (2018) demonstrated that the birds 
were not protected throughout production. Without vacci-
nation after 19 weeks, the birds failed to be protected after 
38 weeks of age; with vaccination after 19 weeks, the birds 
failed to be protected around 58 weeks of age. The data clearly 
demonstrated showed that with laying or breeder birds the dura-
tion of immunity is one of the main limitation issues for life 
cycle protection in the field, especially in the smallholder setting.
Among the recombinant viral-vectored vaccines, the rHVT-
AIV has the advantage that it can be used in day-old chicks 
at the hatchery. This vaccine has shown some good results in 
field studies in Egypt and is currently licensed in five countries 
(Bangladesh, Egypt, Mexico, Vietnam and the USA (von 
Dubschuetz, 2013).
Need for regular AI vaccine reformulation
Due to the antigenic drift of the AI virus in the field, there 
is a need to constantly update the composition of AI vac-
cines. This can be achieved only through constant monitor-
ing of the virus strains in the field, rapid regulatory review 
and approval process and, good manufacturing processes. As 
the largest user of AI vaccines, the evolution over time of the 
vaccinal strains used in China is quite indicative of the need 
for regular reformulation, both for killed and live vaccines 
(Table 3).
Over the course of 10 years, the control of H5N1 in China has 
required the introduction of seven different killed vaccines. In 
addition, H5N1 has also been combined with H9N2 for better 
vaccination coverage, adding two new killed vaccine formula-
tions (Fan et al., 2015). In 2017, a vaccine combining H7N9 
with H5N1 was approved for use in poultry (Shi et al., 2018). 
The need for the regular updating of H5N1 viral subtypes is 
also required for live recombinant NDV-vectored vaccines, with 
three different formulations (rLH5-1, rLH5-5 and rLH5-6) 
approved since 2005 (Fan et al., 2015). The need for regular 
updating of vaccinal strains was also reported by Tarigan et al. 
(2018) in Indonesia, another country using vaccination to con-
trol avian influenza on a wide scale since the first outbreak 
was reported in 2003 (Table 4).
Due to the antigenic drift of the AI virus in the field, the geo-
graphical coverage of AI vaccines is very specific and sometimes 
limited to certain provinces or districts in a country. Therefore, 
most AI vaccines administered in China, Pakistan, Indonesia 
and Egypt are produced by local manufacturers.
Key learnings from national AI vaccination campaigns
Since 2002 with the use of vaccines to control H5 HPAI in 
Hong Kong, mass AI vaccination campaigns have been imple-
mented in China, Vietnam, Indonesia, Egypt and Mexico. Key 
learnings were shared by these countries during the OFFLU 
technical meeting in Beijing, China and reported in the recom-
mendations issued (OFFLU, 2013). A number of authors have 
also reviewed the performance of vaccination campaigns in 
Egypt (Kaoud, 2017), Indonesia (Swayne et al., 2015), Asia 
(Peyre et al., 2009) and globally (Pavade et al., 2011) as 
well as the economic cost and benefits (Hinrichs et al., 2012; 
Hinrichs, 2013; Sun et al., 2017). 
The key learnings from these national AI vaccination campaigns 
are summarized below:
•   Antigenic drift occurs with all AI viruses and can reduce 
the effectiveness of vaccination over time. It is essential to 
use vaccinal strains with sufficient quantities of antigens 
reasonably well matched with circulating strains of AI virus.
Table 3. Evolution of the H5N1 viral strains used in killed 
vaccines in China (2004–2014).
Year Viral strains in H5N1 vaccines used in China
2004 Heterologous H5N2 strain, killed
2005 H5N1 Re-1, killed 
2006 – 2012 Killed H5N1 Re-4, Re-5, Re-6 and bivalent 
vaccines killed H5N1 Re-1/Re-4, Re-4/Re-5 and 
Re-4/Re-6
2014 H5N1 Re-7, killed
Table 4. Evolution of the H5N1 viral 
strains used in killed vaccines in 
Indonesia (2004–2012).
Year Viral strains in H5N1 
vaccines used in Indonesia
2004 H5N1 subclade 2.1.1
2008 H5N1 subclade 2.1.2 and 2.1.3
2012 H5N1 subclade 2.3.2.1
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•   Vaccination with high-quality, registered vaccines, according 
to established protocols reduces resistance to infection, decreases 
viral shedding and decreases the probability of infection to 
poultry, other animals and humans.
•   Vaccination only partially reduces viral shedding and can pro-
mote, especially if not conducted correctly, depending on the 
choice of vaccine, mode and frequency of administration, the 
selection of mutation in the circulating virus.
•   Vaccination alone cannot eliminate the virus and is only meant 
to be part of an integrated, holistic control program adapted 
to local conditions
•   It is difficult to maintain high level flock immunity in some 
poultry populations, especially at small production and backyard 
levels.
•   Vaccination is logistically demanding, and additional costs 
will be initially incurred in countries lacking efficient cold chain 
distribution networks required for most vaccines.
•   Vaccination is expensive due to the need to conduct high qual-
ity post-vaccination surveillance to monitor the genetic and 
antigenic characteristics of circulating field viruses.
•   The return on investment of vaccination must be carefully 
considered before adding vaccination as part of an AI control 
programme.
In Indonesia, a survey of commercial egg producers (Brum, 
2013) showed that AI vaccinations were ineffective for the fol-
lowing reasons: poor selection of vaccinal strains vs. field chal-
lenge, first AI vaccine given too late and, not enough booster 
vaccinations, especially during the period of egg production 
(when vaccination will cause a reduction in egg production). 
Farmers also lacked independent high-quality technical sup-
port and 55% of the respondents said that they needed better 
information on vaccine selection and the vaccination schedule.
Regarding the situation in countries with large backyard poul-
try production, Alders et al. (2007); Gardner et al. (2014); 
Pavade et al. (2011) and Sims et al. (2016) have provided some 
additional points to consider:
•   Backyard poultry are extremely hard to reach, and the exer-
cise remains extremely costly. Thus, vaccination should not be 
started if adequate funding for the preparation, implementation 
and monitoring cannot be guaranteed.
•   As a rule, it is not recommended to vaccinate backyard poul-
try since maintaining adequate levels of immunity is extremely 
difficult.
•   Community vaccinators are often reluctant to vaccinate 
backyard birds under 2 months of age for fear of killing them, 
thereby missing about 50% of the birds at risk.
•   Vaccination is not a substitute for other important measures 
like biosecurity and can give farmers a false sense of security.
•   Poor vaccination practices, insufficient vaccination coverage 
and lack of post-vaccination monitoring (as often seen in devel-
oping countries with large backyard poultry populations) can 
contribute to an endemic situation.
Overview on government AI control
Information on national regulations and policies related to AI 
vaccination is available via the World Animal Health Informa-
tion System (WAHIS) interface hosted by the OIE (OIE, 2019). 
This database is built from information submitted to the OIE 
by its 184 country members. Among the parameters recorded, 
the following information is relevant to this paper: vaccination 
prohibited and official vaccination. It must be noted that official 
vaccination is not necessarily the converse of vaccination pro-
hibited. Vaccination against poultry diseases may be the result of 
official vaccination and / or voluntary vaccination.
According to the OIE website (OIE, 2019), the countries with 
official AI vaccination programs are Mexico, Egypt, Pakistan, 
Kazakhstan and Russia. China also has official AI vaccination. 
Vaccination is also allowed in Bangladesh where import per-
mits are delivered to the private sector and killed AI vaccines 
imported (no combination vaccines used). Vietnam, Egypt and 
Indonesia have transitioned from mass vaccination to targeted 
vaccination (OFFLU, 2013). The cost of AI vaccination is 
often shared between governments and the private sector. 
For instance, in Vietnam, farmers with >2,000 birds pay the full 
cost of vaccination while farmers with <2,000 birds receive 
some provincial subsidies. 
Regional organizations like the African Union and the Asso-
ciation of South-East Asian Nations do not have specific policies 
regarding AI except for the desire to strengthen the linkages 
within countries and across borders, for the sharing of infor-
mation and knowledge and for the development of partnership 
between all stakeholders in public and private sectors and civil 
society.
At the intergovernmental level, the Network of Expertise on 
Animal Influenza (OFFLU), a joint OIE-FAO technical com-
mittee with a worldwide network of contributors, issued in 
2013 a series of recommendations on vaccination and vaccines 
(OFFLU, 2013).
The ideal AI vaccine candidate for poultry 
smallholders
The desired attributes (product profile) for AI vaccines targeting 
the smallholder segment, as suggested by Swayne et al. (2019) 
are presented in Table 5.
Based on the views of a number of experts from academia, 
governments, intergovernmental organizations and the private 
sector, the top desired attributes for the smallholder segment are 
listed in Table 6.
Due to the genetic drift of the AI viruses, the current com-
mercial vaccines have a limited geographical coverage and 
use. The development of a universal vaccine would allow for 
the same commercial vaccine to be used in all major countries 
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Table 5. Desired attributes of AI vaccines addressing the smallholder segment.
Desired attribute Current situation
Inexpensive Current cost for inactivated AIV vaccine: $0.03–0.10/dose plus cost of administration 
($0.05–0.07 per dose for individual handling and injection) 
Use in multiple avian 
species
Most vaccines are used in meat, layer and breeder chickens although a large number of 
doses also used in ducks; minor amounts in turkeys, geese, quail, etc. 
Single dose protection Most situations require a minimum of 2 doses; prime-boost scenario is optimal with 
revaccination in long-lived birds at 6–12-month intervals 
Mass application 95.5% is inactivated vaccine administered by handling and injecting individual birds and 4.5% 
as vectored vaccine given by mass spray vaccination 
Identify infected birds in 
vaccinated population (DIVA)
Serological differentiation tests are available, but only minor use. Most vaccine applied 
without using a serological DIVA strategy for surveillance
Overcome maternal 
antibody interference
Maternal antibody to AIV hemagglutinin or virus vector inhibits primary immune response. 
Initial vaccination must be timed for declining maternal antibody titers to allow optimal 
primary immune response
Given at 1 day of age in 
hatchery or in ovo
Inactivated vaccine provides poor protection when given at 1 day of age. Vectored vaccines 
can be given at 1 day of age, but generally require a boost with inactivated vaccine 10 days 
or more later
Universal vaccine The majority of inactivated whole AIV vaccines use reverse genetic generated vaccine seed 
strains to antigenically match field viruses. The vaccinal strain of virus should also be a 
strong immunogen
Thermostable Killed AI vaccines, rNDV-AI and rFPV-AI vaccines require refrigeration and rHVT-AI vaccine 
must be stored in liquid nitrogen
Table 6. Desired attributes of AI vaccines addressing the smallholder segment.
Desired 
attribute
Rationale
Universal 
vaccine
The antigenic drift of the AI viruses in the field requires a constant surveillance usually 
poorly performed by national veterinary services in developing countries due to the lack 
of proper facilities, human and financial resources. In addition, the availability of universal 
vaccines would eliminate the need to regularly update vaccines, often affected by 
inefficient national regulatory review and approval processes for vaccines
Use in multiple 
species
Ducks often act as silent carriers, shedding AI virus without expressing clinical signs. An 
effective vaccine in ducks as well as chickens would be of greater value, especially in South 
East Asia 
Single dose 
protection
The biggest logistical hurdle and highest cost of AI vaccination is related to the handling 
and injection of each bird. A vaccine conferring at least a 6-month protection after one 
single administration would maximize the value of mass vaccination campaigns
currently vaccinating against AI (China, Egypt, Indonesia, 
Vietnam and Mexico). Such a vaccine would be also available in 
countries considering adding vaccination to their AI con-
trol measures even though the current trend shows that fewer 
countries are willing to initiate AI vaccination. 
Conclusion
Vaccination against HPAI has been used as one of the tools 
in national AI control programmes with varying degrees of 
successes. Few countries have been able to eradicate HPAI 
and these countries have typically relied on extremely compe-
tent national veterinary services and / or had limited poultry 
population at risk. Current vaccines, when well-matched to field 
strains (in quantity and quality), administered properly (tim-
ing, frequency and method of administration) and combined 
with a wide range of other measures have prevented financial 
losses in poultry farms and reduced the risks to human 
populations.
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The cost of AI vaccines is only a small part of the overall cost 
of vaccinating poultry against AI, especially when targeting 
poultry smallholders in lower- and middle-income countries. 
The current vaccine production technologies and vaccines 
have not been able to address the cost inherent to their use. 
In order to represent a significant advance, the profile for 
vaccine candidates must include protection against all viral 
strains (universal vaccine), efficacy in ducks with reduc-
tion in viral shedding and, protection after a single admin-
istration. Without the inclusion of these properties in the 
vaccine profile, it is unlikely that any vaccine candidate 
would add significant value to the current AI vaccine 
market and thus warrant the investment of funds for its 
development.
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